Barrett Katz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J P Morgan Healthcare Conference

- VRDN-001 topline clinical results for THRIVE and THRIVE-2 on track for mid-2024 and year-end 2024 in patients with active and chronic thyroid eye disease , respectively - - Subcutaneous VRDN-003.

United statesSan franciscoClearside bioBarrett katzSteve mahoneyCompensation committeeViridian therapeutics incKey program milestonesExchange commissionViridian therapeuticsChief executive officerHealthcare conferenceInvestigational new drug applicationEye disease portfolioFcrn portfolioThomas ciulla

Viridian Stock: Market May Be Wrong In Its Disapproval (NASDAQ:VRDN)

Viridian Stock: Market May Be Wrong In Its Disapproval (NASDAQ:VRDN)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Barrett katzViridian therapeutics incDigital eyeViridian therapeuticsThyroid eye diseaseChief medical officer barrett katz

Viridian Therapeutics (VRDN) Reports Positive Data from Ongoing Phase 1/2 Trial of VRDN-001

Viridian Therapeutics (VRDN) Reports Positive Data from Ongoing Phase 1/2 Trial of VRDN-001
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoKimberly cockerhamBarrett katzMatt fearerTodd jamesViridian therapeutics incCorporate affairsDrug administrationNeither the companyCompany quarterly report on formCorporate communicationsExchange commissionViridian therapeuticsOculoplastic surgeonChief medical officer

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

- VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg – - Ongoing THRIVE Phase 3 trial in patients with active TED amended to reflect Viridian’s confidence in 5-dose regimen and key stakeholder feedback on evolving TED treatment paradigm - - THRIVE-2 Phase 3 trial in patients with chronic TED expected to start in third quarter 2023 – - 3 mg/kg data support low-volume subcutaneous (SC) dosing profile for Company’s SC candidates in TED - - Viridian plans to select lead SC program candidate by year-end 2023; VRDN-001 SC IND amendment and VRDN-003 IND submitted to the FDA – - Conference call and webcast to be held today, Monday, July 10th at 5:00 p.m. ET -

United statesSan diegoBarrett katzKimberly cockerhamNeither the companyExchange commissionCompany quarterly report on formDrug administrationViridian therapeutics incViridian therapeuticsOculoplastic surgeonChief medical officerThyroid eye disease pipelinePrivate securities litigation reform actThyroid eye diseaseQuarterly report

Viridian Therapeutics (VRDN) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN – Get Rating) in a research report released on Monday, Benzinga reports. They currently have a $47.00 target price on the stock. A number of other brokerages also recently commented on VRDN. B. Riley boosted their price objective on Viridian Therapeutics […]

Scott dunseth myersBarrett katzStifel nicolausNeedham companyChartwell investment partnersCredit suisse groupVoya investment managementMetlife investment managementViridian therapeutics company profileViridian therapeutics incLife insurance coSecurities exchange commissionViridian therapeuticsGet ratingSuisse groupDunseth myers